151385-64-7

Upstream product

• 28898-02-4 N-(2-Fluorophenyl)-2-nitrobenzeneamine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 348-54-9 2-Fluoroaniline 
• 28898-03-5 N-(2-fluorophenyl)benzene-1,2-diamine 
• 107-82-4 i-pentyl bromide 

Downstream Products

• 151385-65-8 2,4-dioxo-5-N-(2-fluorophenyl)-1-N-(3-methylbut-1-yl)-3-phenylhydrazono-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 153930-31-5 2,4-dioxo-5-N-(2-fluorophenyl)-3-isocyanato-1-N-(3-methylbut-1-yl)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151620-15-4 2,4-dioxo-5-N-(2-fluorophenyl)-1-N-(3-methylbut-1-yl)-3-(phenyloxycarbonylamino)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151386-23-1 3-amino-2,4-dioxo-5-N-(2-fluorophenyl)-1-N-(3-methylbut-1-yl)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 

Relevant academic research and scientific papers

Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazephines as cholecystokinin-B receptor antagonists

A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective C

Novel 1,5-benzodiazepines as CCK-B ligands. Effect of aryl-carbamic substituents at the C-3 position together with halogen substitution on the benzo-fused ring

The synthesis and biological evaluation as potential CCK-B receptor ligands of a number of 1-isopentyl-3-aryloxycarbamoyl-5-aryl-1,5-benzodiazepines substituted with halogen atoms on the benzo-fused ring is here briefly discussed.